Jonathan G Leung1, Sarah Nelson2, Sara Hocker3. 1. Department of Pharmacy, Mayo Clinic, 1216 2nd Street SW, Rochester, MN, 55902, USA. Leung.jonathan@mayo.edu. 2. Department of Pharmacy, Mayo Clinic, 1216 2nd Street SW, Rochester, MN, 55902, USA. 3. Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Hemodynamic augmentation is utilized as a treatment in the setting of symptomatic cerebral vasospasm. This approach includes the use of vasopressors to induce hypertension with the aim of improved cerebral blood flow. Agents with potent alpha-1 antagonism properties, including clozapine, can inhibit or blunt the response of several vasopressor agents. METHODS: Case report. RESULTS: A 54-year-old schizophrenic male with an aneurysmal subarachnoid hemorrhage required hemodynamic augmentation in which several vasopressor trials resulted in no or poor response. The addition of epinephrine resulted in a decrease of mean arterial pressure. Vasopressin initiation demonstrated an immediate vasopressor effect. CONCLUSIONS: Vasopressors are an important treatment modality in symptomatic cerebral vasospasm. This case highlights the potential for clozapine to blunt the effects of vasopressors; or in the case of epinephrine, it causes a reversal effect. Vasopressin may be considered an agent of choice in patients who have recently taken clozapine and require hemodynamic augmentation.
BACKGROUND: Hemodynamic augmentation is utilized as a treatment in the setting of symptomatic cerebral vasospasm. This approach includes the use of vasopressors to induce hypertension with the aim of improved cerebral blood flow. Agents with potent alpha-1 antagonism properties, including clozapine, can inhibit or blunt the response of several vasopressor agents. METHODS: Case report. RESULTS: A 54-year-old schizophrenic male with an aneurysmal subarachnoid hemorrhage required hemodynamic augmentation in which several vasopressor trials resulted in no or poor response. The addition of epinephrine resulted in a decrease of mean arterial pressure. Vasopressin initiation demonstrated an immediate vasopressor effect. CONCLUSIONS: Vasopressors are an important treatment modality in symptomatic cerebral vasospasm. This case highlights the potential for clozapine to blunt the effects of vasopressors; or in the case of epinephrine, it causes a reversal effect. Vasopressin may be considered an agent of choice in patients who have recently taken clozapine and require hemodynamic augmentation.
Authors: E Sander Connolly; Alejandro A Rabinstein; J Ricardo Carhuapoma; Colin P Derdeyn; Jacques Dion; Randall T Higashida; Brian L Hoh; Catherine J Kirkness; Andrew M Naidech; Christopher S Ogilvy; Aman B Patel; B Gregory Thompson; Paul Vespa Journal: Stroke Date: 2012-05-03 Impact factor: 7.914
Authors: T M Shiovitz; T L Welke; P D Tigel; R Anand; R D Hartman; J J Sramek; N M Kurtz; N R Cutler Journal: Schizophr Bull Date: 1996 Impact factor: 9.306
Authors: Maria E Baldwin; R Loch Macdonald; Dezheng Huo; Roberta L Novakovic; Roberta L Novakovia; Fernando D Goldenberg; Jeffrey I Frank; Axel J Rosengart Journal: Stroke Date: 2004-10-07 Impact factor: 7.914
Authors: Timothy David Tanzer; Thomas Brouard; Samuel Dal Pra; Nicola Warren; Michael Barras; Steve Kisely; Emily Brooks; Dan Siskind Journal: Ther Adv Psychopharmacol Date: 2022-05-24
Authors: Jessica W Y Yuen; David D Kim; Ric M Procyshyn; Randall F White; William G Honer; Alasdair M Barr Journal: Front Neurosci Date: 2018-04-04 Impact factor: 4.677